logo

For the Inventor, By the Inventor

Stockholm, Sweden

Vicore Pharma Ab

Calculating rank
USPTO Granted Patents = 18

% Expired Patents = 27.8


Trademarks = 4

Forward Citations = 20

Loading Chart...
Loading Chart...

21 inventors (with patents filed for the assignee):

goldMedal Anders Rudolf Hallberg (7 out of 9 patents)

silverMedal Mathias Alterman (5 out of 8 patents)

bronzeMedal Carl-Johan Dalsgaard (4 out of 6 patents)

4.  Rohit Batta (4 out of 4 patents)

5.  Ola Camber (4 out of 4 patents)

6.  Bengt Ohlsson (3 out of 6 patents)

7.  Tomas Fex (3 out of 4 patents)

8.  Xiongyu Wu (2 out of 2 patents)

9.  Mats Larhed (2 out of 5 patents)

10.  Johan Raud (1 out of 3 patents)

11.  Ulrike Steckelings (1 out of 1 patent)

12.  Thomas Unger (1 out of 1 patent)

13.  Murugaiah Andappan Murugaiah Subbaiah (1 out of 1 patent)

14.  Christina Johansson (1 out of 1 patent)

15.  Stefan Grudén (1 out of 1 patent)


18 patents:

1. 12715864 - Process for the synthesis of N-butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-iso-butylthiophene-2-sulfonamide (2026-08-25),
2. 12708615 - SELECTIVE ANGIOTENSIN II RECEPTOR LIGANDS (2026-08-18),
3. 12605341 - Dry powder composition for peroral administration (2026-04-21),
4. 12441718 - Selective angiotensin II compounds (2025-10-14),
5. 12435072 - Compounds (2025-10-07),
6. 12213961 - Treatment of idiopathic pulmonary fibrosis (2025-02-04),
7. 12128029 - Treatment of idiopathic pulmonary fibrosis (2024-10-29),
8. 12121614 - Delayed release composition for peroral administration (2024-10-22),
9. 11844868 - Dry powder composition for peroral administration (2023-12-19),
10. 11819494 - Treatment of idiopathic pulmonary fibrosis (2023-11-21),
11. 11654115 - Delayed release composition for peroral administration (2023-05-23),
12. 11123329 - Use of angiotensin II type 2 receptor agonist (2021-09-21),
13. 8835471 - Use of angiotensin II agonists (2014-09-16),
14. 8357710 - Bicyclic angiotensin II agonists (2013-01-22),
15. 8124638 - Tricyclic compounds useful as angiotensin II agonists (2012-02-28),
Company Overview
Vicore Pharma AB is a biopharmaceutical company based in Stockholm, Sweden, focused on developing innovative therapies for rare and severe respiratory diseases. The company specializes in the research and development of novel treatments that target the underlying mechanisms of these conditions, leveraging its expertise in pharmacology and drug development. Vicore aims to address unmet medical needs through its advanced therapeutic approaches, contributing to improved patient outcomes in the field of respiratory health.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

18 Patents

#52 in Stockholm

#365 in Sweden

#34,263 in the World

Stockholm, SE
Stockholm, Sweden

Vicore Pharma Ab

Forward Citations = 20

21 inventors:

goldMedal Anders Rudolf Hallberg (7 out of 9 patents)

silverMedal Mathias Alterman (5 out of 8 patents)

bronzeMedal Carl-Johan Dalsgaard (4 out of 6 patents)

4.  Rohit Batta (4 out of 4 patents)

5.  Ola Camber (4 out of 4 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Vicore Pharma Ab. Retrieved from https://idiyas.com/company/vicore-pharma-ab

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…